Evidence map›Paper›PMID 41406950›Full record

ArticleCell reports. Medicine2025

Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering.

Jiaqi He, Chunguang Zhang, Chao Liang, Wenchi Xue, Yongheng Li, Lili Dai, Chunyuan Liu, Wan-Ru Zhuang, Xianbin Ma, Ran Cheng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiaqi HeSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Chunguang ZhangState Key Laboratory of Crop Gene Resources and Breeding, Institute of Crop Sciences, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
Chao LiangSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Wenchi XueSchool of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Yongheng LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China.
Lili DaiDepartment of Respiratory and Digestive, Qian'an Yanshan Hospital, Tangshan 064400, China.
Chunyuan LiuDepartment of Otorhinolaryngology, Qian'an Yanshan Hospital, Tangshan 064400, China.
Wan-Ru ZhuangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Chemical Biology Center, Peking University, Beijing 100191, China.
Xianbin MaSchool of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Ran ChengSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Yao LeiState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Chemical Biology Center, Peking University, Beijing 100191, China.
Weidong NieSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China. Electronic address: victornia@bit.edu.cn.
Hai-Yan XieState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Chemical Biology Center, Peking University, Beijing 100191, China; Peking University Ningbo Institute of Marine Medicine, Ningbo 315832, China. Electronic address: hyanxie@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We engineer a tumor-targeted genetic plasmid vector (P

Indexed as

Genetic EngineeringImmunotherapyNeoplasmsT-LymphocytesAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansImmunotherapy, AdoptiveMiceReceptors, Chimeric AntigenTelomeraseReceptors, Chimeric AntigenTelomeraseanti-CD3 scFvchimeric antigen receptor T cellimmune checkpoint inhibitor“immune-cold” solid tumorLIGHTT cell immunotherapytumor-specific genetic engineering

Identifiers

PMID41406950
PMCPMC12765953

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.